Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma.

The article focuses on the efficiency of the nuclear factor (NF)-ΚB pathway in the treatment of multiple myeloma (MM). It talks about the pathway treatment strategy despite being efficient has not yet been approved in the pharmaceutical industry due to the associated toxicities. It tells about alternative agents like the immunomodulatory drugs and proteasome inhibitors are unable to specifically target the cancer cells in the body.